Lupin unveils Glucagon for Injection for severe hypoglycemia in patients with diabetes mellitus in US

In July, Lupin also launched Loteprednol Etabonate Ophthalmic Suspension, 0.5%, in the United States, following United States Food and Drug Administration (USFDA) approval last year. Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. It is also indicated for the treatment of post-operative inflammation following ocular surgery.

Read also: Lupin rolls out Loteprednol Etabonate Ophthalmic Suspension, 0.5% in US

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company has a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally.

Read also: Lupin, Zentiva ink pact to commercialize arthritis drug Certolizumab Pegol